Skip to main content

Advertisement

Table 3 Dichotomized distribution of MPO and IL-17 according to defined cut-offs (22 cells/punch for MPO and 1 cell/punch for IL-17 [27] in primary carcinomas (n = 47)a

From: MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity

  MPO-/IL17- n = 21 (100 %) MPO+/IL17- n = 8 (100 %) MPO-/IL17+ n = 12 (100 %) MPO+/IL17+ n = 6 (100 %) p-value
Age (median, range) 62 (39–77) 59.5 (50–65) 57 (34–72) 55 (45–73) 0.742
FIGO stage
 II 0 0 1 (8.3) 0 0.029
 IIIA 1 (4.7) 0 0 0
 IIIB 2 (9.5) 0 0 3 (50.0)
 IIIC 17 (81.1) 5 (62.5) 8 (66.7) 2 (33.3)
 IV 1 (4.7) 3 (37.5) 3 (25.0) 1 (16.7)
Residual disease
 None 9 (42.9) 2 (25.0) 3 (25.0) 2 (33.3) 0.262
 <2 cm 6 (28.6) 1 (12.5) 7 (58.3) 3 (50.0)
 >2 cm 5 (23.8) 5 (62.5) 2 (16.7) 1 (16.7)
Numbers of chemotherapy cycles
 <6 5 (23.8) 0 1 (8.3) 1 (16.7) 0.412
 6 or more 15 (71.4) 8 (100.0) 11 (91.7) 5 (83.3)
CSb 14 (66.7) 2 (25.0) 11 (91.7) 6 (100.0) 0.004
CRb 7 (33.3) 6 (75.0) 1 (8.3) 0
RFSc (mean/SE) 8.1 (1.7) 3.9 (1.6) 14.9 (3.3) 16 (3.9) 0.024
OSc (mean/SE) 36 (4.5) 33.4 (9.6) 52.4 (12.1) 72 (15.0) 0.113
  1. Bold data statistically significant p < 0.05
  2. apercentages may not add to 100 % due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Fisher’s Exact test
  3. bCS chemosensitive, CR chemoresistant
  4. cRFS recurrence-free survival, OS overall survival